Molecular targets of isothiocyanates in cancer: Recent advances

Authors

  • Parul Gupta,

    1. Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA
    Search for more papers by this author
  • Bonglee Kim,

    1. Cancer Preventive Material Development Research Center, Department of Pathology, College of Korean Medicine, Kyunghee University, Seoul, South Korea
    Search for more papers by this author
  • Sung-Hoon Kim,

    1. Cancer Preventive Material Development Research Center, Department of Pathology, College of Korean Medicine, Kyunghee University, Seoul, South Korea
    Search for more papers by this author
  • Sanjay K. Srivastava

    Corresponding author
    1. Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA
    2. Cancer Preventive Material Development Research Center, Department of Pathology, College of Korean Medicine, Kyunghee University, Seoul, South Korea
    • Correspondence: Professor Sanjay K. Srivastava, Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Suite 1103 ARB, 1406 Coulter Drive, Amarillo, TX 79106, USA

      E-mail: sanjay.srivastava@ttuhsc.edu

      Fax: +1-806-356-4770

    Search for more papers by this author

Abstract

Cancer is a multistep process resulting in uncontrolled cell division. It results from aberrant signaling pathways that lead to uninhibited cell division and growth. Various recent epidemiological studies have indicated that consumption of cruciferous vegetables, such as garden cress, broccoli, etc., reduces the risk of cancer. Isothiocyanates (ITCs) have been identified as major active constituents of cruciferous vegetables. ITCs occur in plants as glucosinolate and can readily be derived by hydrolysis. Numerous mechanistic studies have demonstrated the anticancer effects of ITCs in various cancer types. ITCs suppress tumor growth by generating reactive oxygen species or by inducing cycle arrest leading to apoptosis. Based on the exciting outcomes of preclinical studies, few ITCs have advanced to the clinical phase. Available data from preclinical as well as available clinical studies suggest ITCs to be one of the promising anticancer agents available from natural sources. This is an up-to-date exhaustive review on the preventive and therapeutic effects of ITCs in cancer.

Ancillary